Article
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.
Cancer discovery - 1 Nov 2021
Pore Nabendu, Wu Song, Standifer Nathan, Jure-Kunkel Maria, de Los Reyes Melissa, Shrestha Yashaswi, Halpin Rebecca, Rothstein Raymond, Mulgrew Kathy, Blackmore Stephen, Martin Philip, Meekin John, Griffin Matthew, Bisha Ina, Proia Theresa A, Miragaia Ricardo J, Herbst Ronald, Gupta Ashok, Abdullah Shaad E, Raja Rajiv, Frigault Melanie M, Barrett J Carl, Dennis Phillip A, Ascierto Maria Libera, Oberst Michael D
Abstract excerpt
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non-small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associated with resistance to the anti-PD-L1 antibody durvalumab (alone/with the anti-CTLA4 antibody tremelimumab) independently of KRAS mutational status, highlighting STK11 as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.